Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 1 1

Status

Completed 31Terminated 11Unknown 7Withdrawn 3Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 13Neoplasms 7Brain Neoplasms 6Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Tongue Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Diseases 1Relapsed Pediatric Solid Tumor 1Recurrence 1Precancerous Conditions 1Optic Nerve Glioma 1Non-squamous Non-small Cell Lung Cancer 1Metastatic Pancreatic Adenocarcinoma 1Medulloblastoma 1Lung Diseases 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Familial ependymoma 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Erlotinib Hydrochloride × Clear all
NCT05904457 2023-06-15

BRISK

Asan Medical Center

Phase 2 Unknown
32 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT02239952 2020-10-08

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Amsterdam UMC, location VUmc

Phase NA Unknown
15 enrolled
CNS

Glioma, Neoplasms

NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
144 enrolled
Thoracic

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT00491816 2017-01-19

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

University of Kansas Medical Center

Phase 2 Unknown
32 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT02015728 2016-12-15

SEED

Seattle Children's Hospital

Phase NA Unknown
20 enrolled

Neoplasms, Recurrence

NCT00591383 2012-07-19

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡